Sep 28, 2022 / 03:15PM GMT
Michael Werner Schmidt - Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
All right. Great. So it's Michael Schmidt again with Guggenheim and the next presenting company is ImmunoGen. With us today, we have Susan Altschuller. Susan is the CFO of the company. Welcome, and thanks for joining us.
So ImmunoGen is one of the few independent ADC platforms out there that is approaching approval of their first product, therefore its wholly owned product. And yes, Susan, why don't you give a quick overview and then we'll do Q&A.
Susan Altschuller - ImmunoGen, Inc. - Senior VP & CFO
Great. So ImmunoGen has been a company for over 40 years, and we are just now independently going to launch our first antibody drug conjugate mirvetuximab. We have a PDUFA date with -- November 28, priority review with FDA. And we're really excited to establish mirvetuximab as the standard of care for folate receptor alpha positive platinum-resistant ovarian cancer.
So exciting times here, and I'm sure we'll talk about the market
ImmunoGen Inc at Guggenheim Nantucket Therapeutics Conference (Virtual) Transcript
Sep 28, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers